Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Eisai Co Stock News

ESAIYOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$6.74

0.233.53%

At close: -

$7.03

0.294.30%

After Hours: 9:17 AM EDT

Eisai Co (ESAIY) Forecast

News

Earnings Eisai Co (ESAIY) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Eisai Co Stock News | OTC:ESAIY | Benzinga

Get the latest news on Eisai Co stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Eisai Co performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, April 16, 2025

Reported Earlier, European Commission Approve...
Benzinga Newsdesk - 15 hours ago

Monday, March 03, 2025

BioArctic And Eisai's Lecanemab Denied By The...
Benzinga Newsdesk - Mar 3, 2025, 4:05AM

Monday, January 27, 2025

Reported Sunday, Eisai And Biogen Achieve FDA...
Benzinga Newsdesk - Jan 27, 2025, 2:18AM

Friday, January 24, 2025

Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
Vandana Singh - Jan 24, 2025, 12:24PM

Tuesday, January 14, 2025

Reported Earlier, Eisai And Biogen Announced ...
Benzinga Newsdesk - Jan 14, 2025, 2:37AM

Friday, November 29, 2024

Reported Wednesday, Eisai and Biogen Introduc...
Benzinga Newsdesk - Nov 29, 2024, 2:56AM

Thursday, November 14, 2024

CHMP Recommends EU Approval For Eisai's Leqem...
Benzinga Newsdesk - Nov 14, 2024, 11:04AM

Thursday, August 22, 2024

Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
Vandana Singh - Aug 22, 2024, 1:45PM

Wednesday, July 03, 2024

Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
Vandana Singh - Jul 3, 2024, 12:13PM

Tuesday, June 11, 2024

Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Nabaparna Bhattacharya - Jun 11, 2024, 2:19PM

Monday, June 10, 2024

Eisai And Biogen Announced FDA Accepts Filing...
Benzinga Newsdesk - Jun 9, 2024, 8:09PM

Wednesday, May 15, 2024

Reported Earlier, Biogen And Eisai Initiated ...
Benzinga Newsdesk - May 15, 2024, 2:51AM

Monday, April 01, 2024

Reported Earlier, Eisai Completed Submission ...
Benzinga Newsdesk - Apr 1, 2024, 2:17AM

Tuesday, November 21, 2023

Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Vandana Singh - Nov 21, 2023, 3:16PM

Monday, September 25, 2023

Biogen And Eisai's LEQEMBI Intravenous Infusi...
Benzinga Newsdesk - Sep 25, 2023, 1:59AM

Friday, August 25, 2023

Merck, Eisai Provide Update On Phase 3 LEAP-0...
Benzinga Newsdesk - Aug 25, 2023, 6:19AM

Friday, July 07, 2023

Stocks Rebound, Dollar Tumbles As June Jobs Data Eases Fed Hike Wagers: What's Driving Markets Friday?
Shanthi Rexaline - Jul 7, 2023, 1:23PM

Thursday, July 06, 2023

FDA Converts Novel Alzheimer's Disease Treatment To Traditional Approval; Action Follows Confirmatory Trial To Verify Clinical Benefit
Happy Mohamed - Jul 6, 2023, 4:48PM

Wednesday, March 22, 2023

iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach
Rachael Green - Sponsored

Monday, March 06, 2023

FDA Accepted Eisai-Biogen's Supplemental Biol...
Benzinga Newsdesk - Mar 6, 2023, 3:45AM

Tuesday, February 28, 2023

Reported Late Monday Feb. 27, Eisai Co. And Biogen Inc. Announce Biologics License Application For Lecanemab Designated For Priority Review By China National Medical Products Administration
Happy Mohamed - Feb 28, 2023, 12:56AM

Friday, February 17, 2023

'Maker Of Promising Alzheimer's Drug Leqembi Expects Full FDA Approval This Summer, Expanded Medicare Coverage' - CNBC
Happy Mohamed - Feb 17, 2023, 9:52AM

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved